Atossa Therapeutics, Inc is a biotechnology business based in the US. Atossa Therapeutics shares (ATOS) are listed on the NASDAQ and all prices are listed in US Dollars. Atossa Therapeutics employs 6 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Atossa Therapeutics
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – ATOS – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
Atossa Therapeutics stock price (NASDAQ: ATOS)Use our graph to track the performance of ATOS stocks over time.
Atossa Therapeutics shares at a glance
|Latest market close||$3.22|
|52-week range||$0.81 - $9.80|
|50-day moving average||$5.62|
|200-day moving average||$3.23|
|Wall St. target price||$7.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.51|
Buy Atossa Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Atossa Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Atossa Therapeutics price performance over time
|1 week (2021-07-19)||N/A|
|1 month (2021-06-30)||-49.05%|
|3 months (2021-04-30)||38.20%|
|6 months (2021-01-26)||N/A|
|1 year (2020-07-26)||N/A|
|2 years (2019-07-26)||N/A|
|3 years (2018-07-26)||N/A|
|5 years (2016-07-26)||N/A|
Atossa Therapeutics financials
|Gross profit TTM||$0|
|Return on assets TTM||-12.43%|
|Return on equity TTM||-24.46%|
|Market capitalisation||$496.6 million|
TTM: trailing 12 months
Shorting Atossa Therapeutics shares
There are currently 20.5 million Atossa Therapeutics shares held short by investors – that's known as Atossa Therapeutics's "short interest". This figure is 24.3% up from 16.5 million last month.
There are a few different ways that this level of interest in shorting Atossa Therapeutics shares can be evaluated.
Atossa Therapeutics's "short interest ratio" (SIR)
Atossa Therapeutics's "short interest ratio" (SIR) is the quantity of Atossa Therapeutics shares currently shorted divided by the average quantity of Atossa Therapeutics shares traded daily (recently around 32.1 million). Atossa Therapeutics's SIR currently stands at 0.64. In other words for every 100,000 Atossa Therapeutics shares traded daily on the market, roughly 640 shares are currently held short.
However Atossa Therapeutics's short interest can also be evaluated against the total number of Atossa Therapeutics shares, or, against the total number of tradable Atossa Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Atossa Therapeutics's short interest could be expressed as 0.17% of the outstanding shares (for every 100,000 Atossa Therapeutics shares in existence, roughly 170 shares are currently held short) or 0.17% of the tradable shares (for every 100,000 tradable Atossa Therapeutics shares, roughly 170 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Atossa Therapeutics.
Find out more about how you can short Atossa Therapeutics stock.
Atossa Therapeutics share dividends
We're not expecting Atossa Therapeutics to pay a dividend over the next 12 months.
Have Atossa Therapeutics's shares ever split?
Atossa Therapeutics's shares were split on a 1:12 basis on 19 April 2018. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Atossa Therapeutics shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Atossa Therapeutics shares which in turn could have impacted Atossa Therapeutics's share price.
Atossa Therapeutics share price volatility
Over the last 12 months, Atossa Therapeutics's shares have ranged in value from as little as $0.81 up to $9.8. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Atossa Therapeutics's is 2.2758. This would suggest that Atossa Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Atossa Therapeutics overview
Atossa Therapeutics, Inc. , a clinical-stage biopharmaceutical company, discovers and develops medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; AT-H201, a drug candidate to improve lung function in COVID-19 patients; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. Atossa Therapeutics, Inc. has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the potential treatment of breast cancer.
Stocks similar to Atossa Therapeutics
Atossa Therapeutics in the news
France stocks higher at close of trade; CAC 40 up 1.19% By Investing.com
Atossa Therapeutics Might Shoot Up Quickly on Covid-19 Fear
Wait for Atossa Therapeutics Stock to Slide Further Before Buying
Frequently asked questionsWhat percentage of Atossa Therapeutics is owned by insiders or institutions?
Currently 0.043% of Atossa Therapeutics shares are held by insiders and 12.591% by institutions. How many people work for Atossa Therapeutics?
Latest data suggests 6 work at Atossa Therapeutics. When does the fiscal year end for Atossa Therapeutics?
Atossa Therapeutics's fiscal year ends in December. Where is Atossa Therapeutics based?
Atossa Therapeutics's address is: 107 Spring Street, Seattle, WA, United States, 98104 What is Atossa Therapeutics's ISIN number?
Atossa Therapeutics's international securities identification number is: US04962H5063 What is Atossa Therapeutics's CUSIP number?
Atossa Therapeutics's Committee on Uniform Securities Identification Procedures number is: 04962H100
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert